

**ASTRAZENECA PHARMA INDIA LIMITED**

Regd. Office : Off Bellary Road, Hebbal, Bangalore 560 024

**FINANCIAL RESULTS FOR THE  
QUARTER AND YEAR ENDED 31st DECEMBER, 2004**

Rs. in lakhs

Sl No.	Particulars	9 months ended 30.09.2004 (Audited)	3 months ended 31.12.2004 (Audited)	Corresponding 3 months in the previous year 31.12.2003 (Audited)	Year to date figures for current year 31.12.2004 (Audited)	Previous Accounting year ended 31.12.2003 (Audited)
1	Net sales/ income from operations	13,823.41	5,223.12	5,025.15	19,046.53	17,610.53
2	Service income	150.31	95.93	117.90	246.24	218.86
3	Other income	252.87	108.87	7.90	361.74	252.20
4	<b>Total expenditure</b>					
	(a) Increase(-) in stock-in-trade	1,484.20	(379.40)	(738.21)	1,104.80	(759.58)
	(b) Consumption of raw materials, packing materials and traded goods	3,800.65	1,834.76	2,248.61	5,635.41	6,851.22
	(c) Staff cost	2,176.04	1,209.47	1,286.34	3,385.51	3,254.95
	(d) Other expenditure	3,033.81	1,681.35	1,591.70	4,715.16	4,419.14
5	Interest	2.88	0.33	2.90	3.21	4.81
6	Depreciation	315.85	125.71	139.92	441.56	468.86
7	Profit before tax (1+2+3-4-5-6)	3,413.16	955.70	619.69	4,368.86	3,842.19
8	Provision for tax	1,346.54	447.29	239.35	1,793.83	1,391.38
9	Net profit (7-8)	2,066.62	508.41	380.34	2,575.03	2,450.81
10	Paid-up Equity Share Capital (Face value of Rs.10 per share)	500.00	500.00	500.00	500.00	500.00
11	Reserves excluding revaluation reserves	NA	NA	NA	11,880.70	9,525.65
12	Basic and diluted earnings (Rs) per share (not annualised)	41.33	10.17	7.61	51.50	49.02
13	Aggregate of non-promoter shareholding					
	- Number of shares	419,509	480,726	419,509	480,726	419,509
	- Percentage of shareholding	8.39%	9.61%	8.39%	9.61%	8.39%

**Notes :**

- The above statement of financial results was reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 16th February 2005.
- The Company's sole business segment is HealthCare. The Capital employed in this segment is Rs 12,380.70 lakhs (12 months ended 31 December 2003: Rs 9,805.66 lakhs).
- There were no investor complaints pending as at the beginning of the period. The Company has received 32 investor complaints during the year ended 31 December 2004 of which 1 complaint is pending settlement due to dispute on ownership of shares. All other complaints have been satisfactorily dealt with.
- Previous period figures have been regrouped/ reclassified, wherever necessary to conform to the current period.
- The Board of Directors in their meeting held on 16 February 2005, have recommended a dividend of Rs.50 per equity share of Rs 10 each for the year ended 31 December 2004, including a special silver jubilee dividend of Rs.45.80 per equity share of Rs.10 each.

**By Order of the Board of Directors  
For ASTRAZENECA PHARMA INDIA LIMITED**

Place : Singapore  
Dated : 16 February 2005

**BHASKER V IYER  
Managing Director**